Market revenue in 2023 | USD 2,338.8 million |
Market revenue in 2030 | USD 3,922.0 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Subunit vaccines |
Fastest growing segment | Subunit Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the Canada vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is anticipated to witness exponential growth opportunities owing to high disease burden of influenza and increasing awareness of vaccination among the population. According to data published by Health Canada, 16,126 laboratory-confirmed influenza cases were reported during the 2021–2022 influenza season.
Thus, the high burden of the disease is compelling government bodies to implement certain initiatives to combat influenza. For instance, in July 2022, the government of Manitoba, Canada, announced an expansion of eligibility for the high-dose influenza vaccine to include adults aged 65 and above for enhanced protection from a life-threatening infection.
Moreover, recent product approvals and ongoing partnerships between market players & governments to increase vaccine supply are propelling the market growth. For instance, in July 2022, GSK plc signed an agreement with the Canadian government for seasonal and pandemic influenza vaccines to help protect Canadian children.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Canada vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account